Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer

被引：4
|
作者：
Kogawa, Takahiro
Yonemori, Kan
Naito, Yoichi
Noguchi, Emi
Shimizu, Chikako
Tamura, Kenji
Hosono, Ako
Matsubara, Nobuaki
Sugihara, Masahiro
Ogawa, Hayao
Majima, Shuji
Yu, Channing
Ueno, Suguru
Takano, Toshimi
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS1116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1116
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Johnson, M.
    Steuer, C.
    Vigliotti, M.
    Shipitofsky, N.
    Guevara, F. M.
    Chen, S.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S815 - S816
  • [2] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Vigliotti, M.
    Shipitofsky, N.
    Singh, J.
    Guevara, F.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2290 - S2290
  • [3] Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
    Janne, Pasi A.
    Yu, Helena Alexandra
    Johnson, Melissa Lynne
    Vigliotti, Michele
    Shipitofsky, Nicole
    Guevara, Ferdinand Morales
    Chen, Shuquan
    Yu, Channing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
    Meulendijks, Didier
    Jacob, Wolfgang
    Martinez-Garcia, Maria
    Taus, Alvaro
    Lolkema, Martijn P.
    Voest, Emile E.
    Langenberg, Marlies H. G.
    Fleitas Kanonnikoff, Tania
    Cervantes, Andres
    De Jonge, Maja J.
    Sleijfer, Stefan
    Soerensen, Morten Mau
    Thomas, Marlene
    Ceppi, Maurizio
    Meneses-Lorente, Georgina
    James, Ian
    Adessi, Celine
    Michielin, Francesca
    Abiraj, Keelara
    Bossenmaier, Birgit
    Schellens, Jan H. M.
    Weisser, Martin
    Lassen, Ulrik N.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 877 - 885
  • [5] Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease
    Krop, Ian
    Masuda, Norikazu
    Kogawa, Takahiro
    Takahashi, Shunji
    Yonemori, Kan
    Inoue, Kenichi
    Nakayama, Takahiro
    Yamamoto, Yutaka
    Alvarez, Ricardo
    Toyama, Tatsuya
    Osaki, Akihiko
    Takahashi, Masato
    O'Shaughnessy, Joyce
    Sagara, Yasuaki
    Saji, Shigehira
    Kaklamani, Virginia
    Oh, Sun Young
    Gradishar, William
    Haley, Barbara
    Iwasa, Tsutomu
    Traina, Tiffany
    Ueno, Naoto
    Isakoff, Steve
    Ohwada, Shoichi
    Tanaka, Yoshimi
    Mekan, Sabeen
    Onuma, Hiroshi
    Sharma, Om
    Iwata, Hiroji
    CANCER RESEARCH, 2020, 80 (04)
  • [6] Single agent activity of U3-1402, a HER3-argeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.
    Kogawa, Takahiro
    Yonemori, Kan
    Masuda, Norikazu
    Takahashi, Shunji
    Takahashi, Masato
    Iwase, Hirotaka
    Nakayama, Takahiro
    Saeki, Toshiaki
    Toyama, Tatsuya
    Takano, Toshimi
    Onuma, Hiroshi
    Ogawa, Hayao
    Tanaka, Yoshimi
    Igari, Yoshiko
    Sugihara, Masahiro
    Vigliotti, Michele
    Yu, Channing
    Olivo, Martin Sebastian
    Ueno, Suguru
    Iwata, Hiroji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
    Andreas Schneeweiss
    Tjoung-Won Park-Simon
    Joan Albanell
    Ulrik Lassen
    Javier Cortés
    Veronique Dieras
    Marcus May
    Christoph Schindler
    Frederik Marmé
    Juan Miguel Cejalvo
    Maria Martinez-Garcia
    Iria Gonzalez
    Jose Lopez-Martin
    Anja Welt
    Christelle Levy
    Florence Joly
    Francesca Michielin
    Wolfgang Jacob
    Céline Adessi
    Annie Moisan
    Georgina Meneses-Lorente
    Tomas Racek
    Ian James
    Maurizio Ceppi
    Max Hasmann
    Martin Weisser
    Andrés Cervantes
    Investigational New Drugs, 2018, 36 : 848 - 859
  • [8] Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
    Schneeweiss, Andreas
    Park-Simon, Tjoung-Won
    Albanell, Joan
    Lassen, Ulrik
    Cortes, Javier
    Dieras, Veronique
    May, Marcus
    Schindler, Christoph
    Marme, Frederik
    Miguel Cejalvo, Juan
    Martinez-Garcia, Maria
    Gonzalez, Iria
    Lopez-Martin, Jose
    Welt, Anja
    Levy, Christelle
    Joly, Florence
    Michielin, Francesca
    Jacob, Wolfgang
    Adessi, Celine
    Moisan, Annie
    Meneses-Lorente, Georgina
    Racek, Tomas
    James, Ian
    Ceppi, Maurizio
    Hasmann, Max
    Weisser, Martin
    Cervantes, Andres
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 848 - 859
  • [9] Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)
    Krop, Ian
    Yonemori, Kan
    Takahashi, Shunji
    Inoue, Kenichi
    Nakayama, Takahiro
    Iwata, Hiroji
    Toyama, Tatsuya
    Yamamoto, Yutaka
    Takahashi, Masato
    Osaki, Akihiko
    Saji, Shigehira
    Sagara, Yasuaki
    O'Shaughnessy, Joyce
    Traina, Tiffany
    Ohwada, Shoichi
    Qi, Zhenhao
    Qiu, Yang
    Onuma, Hiroshi
    Sharma, Om
    Mekan, Sabeen
    Masuda, Norikazu
    CANCER RESEARCH, 2021, 81 (04)
  • [10] Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial
    Yonemori, K.
    Masuda, N.
    Takahashi, S.
    Kogawa, T.
    Nakayama, T.
    Yamamoto, Y.
    Takahashi, M.
    Toyama, T.
    Saeki, T.
    Iwata, H.
    ANNALS OF ONCOLOGY, 2019, 30
12345